Published in Translational Psychiatry, the study then demonstrated that a cancer medication has the potential to reverse this early-stage hyperconnectivity.

The research, conducted in brain cells of rats, showed that low levels of the protein amyloid-beta could induce hyperconnectivity and this pattern closely resembled changes seen in the brains of people of people with Mild Cognitive Impairment. Amyloid-beta is thought to be instrumental in Alzheimer’s disease, where it creates plaques – or sticky clumps of amyloid-beta proteins – around the neurons.

These new findings suggest that low levels of amyloid-beta alone are enough to trigger early, disease-relevant changes in how brain cells connect.

Read it HERE

JACKSONVILLE, Fla. — In a study published in Nature Communications, Mayo Clinic researchers have identified specific DNA-level changes in the brains of people with Alzheimer’s disease (AD). Using advanced biological analysis, the team mapped alterations in the brain’s regulatory landscape that may help explain why Alzheimer’s presents and progresses differently from person to person. The findings could also open new avenues for understanding other neurodegenerative diseases.

Read more HERE

New research reveals the adult brain generates fresh nerve cells in the hippocampus, vital for memory. This ability declines in Alzheimer’s patients. Scientists observed this process in postmortem brain samples. Healthy older adults show continued neuron production.

Read more at:
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/brain-can-keep-producing-new-neurons-in-old-age-but-alzheimers-may-disrupt-the-process-study/articleshow/128914343.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

A team co-led by UCL researchers has reversed Alzheimer’s disease pathology in mice using nanoparticles that help the brain to clear away toxic amyloid proteins naturally.

9 October 2025

A team co-led by UCL researchers has reversed Alzheimer’s disease pathology in mice using nanoparticles that help the brain to clear away toxic amyloid proteins naturally.

Unlike traditional nanomedicine, which relies on nanoparticles as carriers for therapeutic molecules, the approach utilised nanoparticles that are bioactive in their own right, known as “supramolecular drugs”. The work has been published in the journal Signal Transduction and Targeted Therapy.

Instead of targeting neurons directly, the therapy restores the proper function of the blood-brain barrier, the vascular gatekeeper that regulates the brain’s environment. By repairing this critical interface, the researchers achieved a reversal of Alzheimer’s pathology in animals.

The brain obtains its energy from a vast blood supply, supported by a unique and dense vascular system, where a single capillary nourishes each neuron.

Read more HERE

A new study published in PLOS Medicine found that increased pollution exposure may be a key driver for risk of Alzheimer’s disease. In a study that examined nearly 27.8 million US Medicare beneficiaries aged 65 years and older over an 18 year time period, it was found that pollution exposure (measured by PM2.5) was associated with a significantly increased risk of Alzheimer’s disease. The research also found that pollution exposure is associated with an increased risk for the development of hypertension, depression and stroke, all of which are independent risk factors themselves for Alzheimer’s and dementia.

Read the full article HERE